Patent Term Adjustment

Patent Term Adjustment (PTA) is a mechanism under 35 U.S.C. § 154(b) that compensates patent holders when the USPTO fails to meet certain processing deadlines during patent prosecution — extending the standard 20-year patent term by the number of days of PTA accrued. The standard U.S. patent term is 20 years measured from the earliest effective U.S. filing date (the priority date). If USPTO processing takes too long, the effective commercial life of the patent is shortened — the patent issues late but still expires 20 years from filing. PTA adds days to the end of the 20-year term to compensate. PTA is computed automatically by the USPTO and stated on the face of each issued patent. It is calculated as: (A Delays + B Delays + C Delays) minus Applicant Delays, minus any days counted in multiple delay categories. Three types of delays give rise to PTA: (1) A Delays: USPTO misses specific processing benchmarks (14 months to first Office action, 4 months to respond to applicant's reply, 4 months to issue after allowance). (2) B Delays: total pendency exceeds 3 years from U.S. filing date. (3) C Delays: delays from interference/derivation proceedings, secrecy orders, or successful appellate review. PTA is distinct from Patent Term Extension (PTE): PTE is available only for FDA-approved drugs, medical devices, food additives, and animal drugs under the Hatch-Waxman Act (35 U.S.C. § 156), and compensates for FDA regulatory delay. A drug patent can receive both PTA (for USPTO delay) and PTE (for FDA regulatory review), but PTE is capped at 5 years and total remaining term after PTE is capped at 14 years.

PTA is calculated as: (A Delays + B Delays + C Delays) − Applicant Delays − Overlapping Delays. A Delays accrue when the USPTO misses specific processing deadlines: first Office action within 14 months of filing; response to applicant reply within 4 months; notice of allowance and patent issuance within 4 months of issue fee payment. Each day beyond these deadlines adds one day of A delay. B Delays accrue automatically when total pendency (from U.S. filing date to issue date) exceeds 3 years. Each day beyond 3 years adds one B-delay day. B delay is capped by RCE filing: any period while an RCE is pending does not count toward B delays. C Delays: specific procedural events — successful appeals (reversal of rejection), interference/derivation proceedings, secrecy orders. Applicant Delay is subtracted from the total. Applicant delay includes: (a) any period exceeding 3 months for the applicant to reply to an Office action (replies within 3 months incur no applicant delay; replies between 3–6 months incur delay days equal to the excess over 3 months); (b) exceeding 3 months to pay the issue fee after Notice of Allowance; (c) filing an IDS after the first Office action (delay counted from OA mail date to IDS filing date); (d) filing a Continued Examination Request (RCE) — the RCE period doesn't add A or B delays and is effectively dead time. Important: overlapping delays between categories are not double-counted. Illustrative example: USPTO takes 18 months to mail first OA (4 months beyond the 14-month A-delay benchmark) = 120 A-delay days. Pendency is 36 months + 60 days = 60 B-delay days. Applicant took 4.5 months to respond to one OA = 45 applicant-delay days. Net PTA = (120 + 60) − 45 = 135 days.

Patent Term Adjustment (PTA) and Patent Term Extension (PTE) are two different mechanisms that both extend patent term beyond the standard 20 years, but they apply to different situations: PTA (35 U.S.C. § 154(b)): compensates for USPTO processing delays during prosecution. Available for all utility patent types. Automatically computed by USPTO. Calculated as USPTO delay days minus applicant delay days. No cap on PTA days — patents with long prosecution can have hundreds of days of PTA. Granted on the issued patent — no separate application needed (though reconsideration can be requested). PTE (35 U.S.C. § 156, Hatch-Waxman): compensates for regulatory delay — specifically, the time a drug, medical device, food additive, animal drug, or veterinary biological product spends in FDA regulatory review before it can be commercialized. Only available for these FDA-regulated product categories. Must be applied for — the patent holder must file a PTE application with the USPTO within 60 days of FDA approval. Calculated as: half the IND period + full NDA/BLA review period. Capped at 5 years maximum extension. Total remaining patent life after PTE cannot exceed 14 years from FDA approval date. For drug patents, both PTA and PTE may apply: the patent may receive PTA for USPTO delays during prosecution, and separately receive PTE for FDA regulatory delay. However, there is an offset: the PTE calculation reduces the extension by the PTA amount (to prevent double-counting). The net result is that drug companies often receive one or the other but not additive amounts from both. Strategy: drug patent applications should be prosecuted quickly (to minimize applicant delays) and PTA carefully preserved to maximize the total available extension.

Yes — patent holders can challenge the USPTO's PTA calculation if they believe errors were made. The USPTO's PTA calculation can be wrong in either direction: the USPTO may overstate applicant delay (subtracting too many days) or miss some A-delay or B-delay days. The challenge process: (1) Request for Reconsideration (37 C.F.R. § 1.705(b)): file within 2 months of the patent grant date. Extensions of time apply and can extend the deadline up to 5 additional months (maximum 7 months from grant). No USPTO fee. The request must specifically identify the alleged error in the USPTO's calculation and explain why the USPTO's determination is incorrect. The USPTO may grant, deny, or partially grant the reconsideration. (2) Civil action in U.S. District Court for the Eastern District of Virginia (35 U.S.C. § 154(b)(4)): if the Request for Reconsideration is denied, the patent holder has 180 days from the USPTO's reconsideration decision to file a civil action in E.D. Va. challenging the PTA. This has generated significant case law — courts have addressed: what constitutes an 'IDS submitted after first OA' for applicant delay purposes; how to count overlapping delays; and whether certain USPTO communication types reset delay clocks. (3) Who can challenge: only the patent holder can challenge PTA — third parties (competitors, infringement defendants) generally cannot directly challenge PTA to reduce the patent's term, though they might raise PTA calculation errors in litigation. Practical value: significant PTA disputes can be worth millions — especially for pharmaceutical patents where each day of additional patent term can be worth tens of millions of dollars in sales exclusivity. IP counsel should review PTA calculations on issuance, particularly for high-value patents or patents that experienced long prosecution.

Yes — Track One prioritized examination reduces PTA accumulation because the USPTO's accelerated processing means fewer A delays and shorter pendency (reducing B delays). This is an intended trade-off: Track One's purpose is to get patents issued faster, which inherently limits the delay compensation that PTA provides. Specific effects: (1) A delays: Track One applications receive first Office actions within 2–4 months (often well within the 14-month A-delay benchmark), so most Track One applications accrue zero A delays from first OA timing. (2) B delays: Track One applications typically issue in 6–12 months, well before the 3-year B-delay threshold. Zero B delay days in most cases. (3) Net PTA: Track One applications typically have very low PTA — often 0 to 30 days total. For industries where speed of issuance is more valuable than extended term (e.g., software, where technology evolves rapidly and a 6-month faster issue date is worth more than 30 extra days at the end of a 20-year term), Track One is clearly beneficial. For pharmaceutical patents where every extra day of exclusivity is worth millions, the PTA trade-off requires careful analysis: if the application is straightforward and likely to issue quickly regardless, Track One makes sense; if prosecution will be complex and generate A/B delays from rejections and responses, Track One may not add enough speed to justify the $4,000 fee while reducing PTA. Patent Prosecution Highway (PPH) similarly accelerates prosecution (via prior foreign allowance) and thus reduces PTA accumulation compared to standard prosecution timelines.